Novopyxis

Novopyxis is a private, preclinical-stage biotech firm pioneering a physics- and mathematics-driven platform for drug discovery and delivery. Its core technology applies knot theory and fluid dynamics to design peptide drugs for uncrystallized protein targets and to engineer a painless, needle-free transdermal delivery system. The company's lead therapeutic candidate, NP-6A, is an AT2R agonist for cardiomyopathy, while its Droplette device aims to deliver large-molecule drugs into the skin. With backing from prestigious academic and government partners, Novopyxis is positioning itself at the intersection of computational biology and advanced medical device engineering.

Ab initio mathematics and physics platform applying knot theory for computational protein structure prediction/de novo peptide design, and fluid physics for a transdermal delivery device (Droplette).

In computational drug discovery, Novopyxis competes with AI/ML-driven biotechs (e.g., Recursion, Exscientia) and structural biology firms. In transdermal delivery, it faces competition from microneedle patch companies (e.g., Vaxxas, Corium) and jet injector systems. Its differentiation lies in its foundational physics/mathematics approach.